C is the answer and the winners are Clement and Area.
Details Below:
Disease-modifying antirheumatic drugs include cytokine inhibitors such as
etanercept and infliximab. These two drugs inhibit tumour necrosis factor, which is an inflammatory mediator that contributes to synovitis and joint
destruction in rheumatoid arthritis. Both drugs are available for parenteral
administration. They are recommended for use in rheumatoid arthritis when
other disease-modifying antirheumatic drugs have failed to achieve symptom
control. As they have been associated with the onset of severe infections,
including tuberculosis, patients should be evaluated for tuberculosis before
treatment and asked to report any signs of infection.
C is the answer and the winners are Clement and Area.
Details Below:
Disease-modifying antirheumatic drugs include cytokine inhibitors such as
etanercept and infliximab. These two drugs inhibit tumour necrosis factor, which is an inflammatory mediator that contributes to synovitis and joint
destruction in rheumatoid arthritis. Both drugs are available for parenteral
administration. They are recommended for use in rheumatoid arthritis when
other disease-modifying antirheumatic drugs have failed to achieve symptom
control. As they have been associated with the onset of severe infections,
including tuberculosis, patients should be evaluated for tuberculosis before
treatment and asked to report any signs of infection.
C
C
A
A